Zacks Investment Research upgraded shares of Simulations Plus, Inc. (NASDAQ:SLP) from a hold rating to a buy rating in a report issued on Tuesday, July 25th. The firm currently has $17.00 target price on the technology company’s stock.
According to Zacks, “Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies. “
Simulations Plus (SLP) traded down 2.41% during trading on Tuesday, reaching $14.20. The company’s stock had a trading volume of 42,803 shares. The company’s 50 day moving average price is $14.17 and its 200-day moving average price is $11.94. The stock has a market cap of $244.88 million, a P/E ratio of 45.08 and a beta of -0.71. Simulations Plus has a 1-year low of $7.90 and a 1-year high of $16.15.
Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Friday, July 14th. The technology company reported $0.13 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.02. Simulations Plus had a net margin of 24.86% and a return on equity of 23.21%. The business had revenue of $6.75 million during the quarter, compared to analyst estimates of $6.48 million. Equities analysts forecast that Simulations Plus will post $0.32 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Friday, July 28th were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Wednesday, July 26th. This represents a $0.20 annualized dividend and a dividend yield of 1.41%. Simulations Plus’s payout ratio is 62.50%.
In related news, CEO Walter S. Woltosz sold 18,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $15.07, for a total transaction of $278,795.00. Following the completion of the sale, the chief executive officer now owns 5,684,916 shares of the company’s stock, valued at $85,671,684.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Argenio David Z. D sold 21,326 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $11.59, for a total transaction of $247,168.34. Following the sale, the director now directly owns 43,775 shares of the company’s stock, valued at approximately $507,352.25. The disclosure for this sale can be found here. Insiders have sold 93,743 shares of company stock valued at $1,154,108 over the last quarter. Company insiders own 36.93% of the company’s stock.
A number of large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its stake in Simulations Plus by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 351,832 shares of the technology company’s stock worth $3,395,000 after buying an additional 13,131 shares during the period. Rice Hall James & Associates LLC increased its stake in Simulations Plus by 2.9% in the first quarter. Rice Hall James & Associates LLC now owns 82,950 shares of the technology company’s stock worth $975,000 after buying an additional 2,304 shares during the period. Crawford Investment Counsel Inc. increased its stake in Simulations Plus by 1.3% in the first quarter. Crawford Investment Counsel Inc. now owns 405,403 shares of the technology company’s stock worth $4,763,000 after buying an additional 5,328 shares during the period. Telos Capital Management Inc. bought a new stake in Simulations Plus during the first quarter worth approximately $246,000. Finally, William Blair Investment Management LLC bought a new stake in Simulations Plus during the first quarter worth approximately $878,000. 30.09% of the stock is owned by institutional investors and hedge funds.
About Simulations Plus
Simulations Plus, Inc (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.